Aurora Spine Corporation

Good morning and welcome to the Aurora Spine Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. To withdraw your question, please press star, then two. Please note, this event is being recorded. I would now like to turn the conference over to Chad Klaus, Chief Financial Officer. Please go ahead.

Good morning, everyone, and thank you for joining us for Aurora Spine Corporation's quarterly earnings conference call. We look forward to discussing our performance for the second quarter of 2024. Before we dive into the details, I'd like to remind everyone that this call will contain forward-looking statements. These statements involve risk and uncertainties, and actual results could differ materially. For a full discussion of these risk and certainties factors, you are encouraged to read or respond to documents on file with CDAR+, including those set forth in periodic reports filed under the forward-looking statements and risk factors section. Statements made during the course of this call may be considered forward-looking statements within the meaning of Section 27A of the Security Acts of 1933 as amended and Section 21E of the Securities Act of 1934. These statements reflect current expectations concerning future events and results. Words such as expect, intend, believe, may, will, should, could, anticipate, and similar expressions are words that are used to identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to risk and uncertainty. and other important factors that could cause actual performance or achievements to materially differ from those projected. The Real Spine does not intend to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. On the call, management may refer to EBITDA, adjusted EBITDA, adjusted net income, and adjusted EPS, which are not measures of financial performance under generally accepted accounting principles or GAAP management believes that these non-GAAP figures in addition to other GAAP measures provide meaningful supplemental information regarding the company's operational performance. Investors should recognize that these non-GAAP figures may not be comparable to similarly titled measures of other companies. These measures should be considered in addition to and not as a substitute for superior or any measure of performance prepared in accordance with GAAP. A reconciliation of non-GAAP measures and the most directly comparable GAAP measures in accordance with SEC regulation G can be found in the company's earnings release. We're joined today by Trent Northcutt, our Chief Executive Officer, and myself, Chad Klaus, our Chief Financial Officer. We will present an overview of our financial performance followed by a Q&A session. I will now turn the call over to Mr. Trent Northcutt, President and Chief

Thank you, Chad. Good morning, everyone. I'm pleased to share our results with the second quarter of 2024, which is our pivotal period for Aurora, with notable progress in both our financial performance, the market penetration, our strategic focus on expanding the sales force and targeting underserved markets has yielded strong results as evidence of our significant sales growth and improved profitability. On Wednesday, we issued a press release detailing our financial results Hopefully, you've had a chance to review the news release, but if not, a copy can be found on our website at auroraspine.com, under the investor section or other financial websites. I'd like to discuss some of the financial and operational highlights from the quarter. We reported revenue of $4.1 million. marked the third consecutive quarter of over $4 million in sales, which represents a 14% increase compared to Q2 2023 and a 24% increase year-over-year. The quarter benefited from strong demand in the pain market sector, particularly for the silent PFX and the ZIP51 implant, driven by targeted marketing, training, and product innovation. Our net loss for the quarter was $0.15 million, significantly narrowing the net loss from $0.482 million in Q2 2023 to earnings per share of $0.00 in Q2 2024. Gross margins improved an impressive 62.4% in Q2 2024 in front of 56.9% in the same period last year. The margin improvement is a direct result from the increased sales of proprietary products and the higher profitability participating in markets with favorable pricing dynamics like ambulatory surgery centers. Operating expenses for Q2 2024 were $2.74 million upfront up from $2.51 million in Q2 2023. The rise in expenses was primarily due to the increased commission and travel associated with expanding our sales force, partially offset by reductions in research and development and professional fees. We generated .348 in operating cash flow, reflecting a strong operational performance and effective working capital management from the management team. Notably, siloed TFX grew by 20.4% from Q1 2024 to Q2 2024, reflecting the success of Aurora's expansion into the pain interventional market. The ZIP51 has doubled in 2024 compared to 2023. The robust growth was attributed to the intensified marketing efforts and increased adoption amongst surgeons. Aurora continues to scale its sales team throughout Q2 directly contributing to the sales surge. The additional and new sales professionals is expected to further drive growth as they onboard more surgeons and more customers for Aurora's ecosystems. The company maintained its commitment to excellence by conducting advanced training sessions for top orthopedic neuro and pain interventional physicians showing the clinical advantages of the Zip, the Silo implants. I'll now hand the call over to Chad Klaus for further discussion of the finances.